Otolaryngology Section, Department of Neuroscience DNS, Padova University, Padova, Italy.
Section of Human Anatomy, Department of Neuroscience DNS, Padova University, Padova, Italy.
Acta Otorhinolaryngol Ital. 2020 Oct;40(5):390-395. doi: 10.14639/0392-100X-N0779.
The interest in surgical routes to the internal auditory canal (IAC) through the external auditory canal for vestibular schwannoma removal has been recently raised by the endoscopic approaches to the lateral skull base. The aim of the study was to reappraise the transmeatal microsurgical approach (TMMa) to the labyrinth and IAC, first described 50 years ago.
A retrospective series of 8 consecutive patients treated for intralabyrinthine and intrameatal schwannomas through TMMa is presented. Main outcome measures consisted of surgical indications, postoperative complications, facial nerve status, bed mobilisation time, hospitalisation time and tumour recurrence rate.
Surgical indications for TMMa were tumour growth (62.5%) and disabling vertigo (37.5%) in the present series. Complete tumour removal with no complications and postoperative normal facial nerve function was obtained in all cases. Bed mobilisation occurred after a median of 3 postoperative days (IQR 2.2-3.0) and discharge after a median of 5.6 days (IQR 4.7-7.0). After a median follow-up of 13 months (IQR 7.5-27.5), no tumour recurrence was observed.
TMMa indications are limited to schwannomas of the labyrinth and IAC, which dropped out from observation protocols due to unmanageable symptoms or growth. Despite the narrow mini-invasive surgical corridor, the TMMa was a safe an effective microsurgical technique in terms of tumour removal and postoperative course.
由于内镜颅底侧方入路的出现,人们对经外耳道入路切除前庭神经鞘瘤的手术入路(IAC)产生了兴趣。本研究旨在重新评估 50 年前首次描述的经外耳道迷路和 IAC 的显微外科入路(TMMa)。
回顾性分析了 8 例连续接受 TMMa 治疗的迷路内和内耳道神经鞘瘤患者的系列病例。主要的观察指标包括手术适应证、术后并发症、面神经状况、下床活动时间、住院时间和肿瘤复发率。
在本研究中,TMMa 的手术适应证为肿瘤生长(62.5%)和致残性眩晕(37.5%)。所有病例均获得了完整的肿瘤切除,无并发症,术后面神经功能正常。术后第 3 天(IQR 2.2-3.0)即可下床活动,术后第 5.6 天(IQR 4.7-7.0)出院。中位随访 13 个月(IQR 7.5-27.5)后,未观察到肿瘤复发。
TMMa 的适应证仅限于迷路和 IAC 的神经鞘瘤,这些肿瘤因无法控制的症状或生长而退出观察方案。尽管微创外科通道狭窄,但 TMMa 在肿瘤切除和术后过程方面是一种安全有效的显微外科技术。